-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting with Pasithea are encouraged to contact in advance to schedule – MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced it will participate as an exhibitor in the upcoming Children's Tumor Foundation (CTF) 2026 NF Conference, held June 26-30, 2026, in Denver, Colorado. “Direct engagement with the clinical and academic NF1 community strengthens our commitment to develop better-tolerated therapies that can be used safely over the long term,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea.